- Presentations
FluoGuide: Q3-Interview
27 November 2024
Redeye interview with Dr. Max Witjes
18 October 2024
FluoGuide Company Update Q2 2024
30 August 2024
Interview with Redeye Analyst
29 August 2024
Redeye Growth Day
30 May 2024
Annual report interview with Redeye
28 February 2024
FluoGuide introduction with HC Andersen Capital
28 February 2024
Redeye Fight Cancer 2024
24 January 2024
Strategy update with SEB
15 January 2024
Redeye interview on strategy update
10 January 2024
Redeye Life Science Day
23 November 2023
Redeye interview on topline data from ph IIb in aggressive brain cancer
14 November 2023
Interview with Dansk Aktionærforeningen (in Danish)
10 November 2023
Redeye interview on topline data from ph IIa in head and neck cancer
8 November 2023
Interview with Redeye
30 October 2023
Redeye Medtech & Diagnostics Seminar
26 September 2023
Interview with Redeye on Q2 report
30 August 2023
Presentation and Q&A on Directed Share Issue
6 July 2023
Should you have any further questions regarding the directed share issue, feel free to send us an e-mail on ir@fluoguide.com
Interview with Redeye on clinical update
8 June 2023
Presentation at Redeye Growth Day
1 June 2023
Presentation at ABGSC Life Science Summit
30-31 May 2023
Presentation at Sedermeradagen in Stockholm
30 May 2023
Presentation at Redeye Orphan Drugs Event
26 April 2023
Redeye Exclusive interview on Annual Report
28 February 2023
Presentation at Økonomisk Ugebrev Life Science Investor Conference
22 February 2023
Dansk Aktionærforening interview (in Danish)
24 Januar 2023
Presentation at Redeye Fight Cancer Seminar
19 January 2023
FluoGuide: Q3-Interview
27 November 2024
Redeye interview with Dr. Max Witjes
18 October 2024
FluoGuide Company Update Q2 2024
30 August 2024
Interview with Redeye Analyst
29 August 2024
Redeye Growth Day
30 May 2024
Annual report interview with Redeye
28 February 2024
FluoGuide introduction with HC Andersen Capital
28 February 2024
Redeye Fight Cancer 2024
24 January 2024
Strategy update with SEB
15 January 2024
Redeye interview on strategy update
10 January 2024
Redeye Life Science Day
23 November 2023
Redeye interview on topline data from ph IIb in aggressive brain cancer
14 November 2023
Interview with Dansk Aktionærforeningen (in Danish)
10 November 2023
Redeye interview on topline data from ph IIa in head and neck cancer
8 November 2023
Interview with Redeye
30 October 2023
Redeye Medtech & Diagnostics Seminar
26 September 2023
Interview with Redeye on Q2 report
30 August 2023
Presentation and Q&A on Directed Share Issue
6 July 2023
Should you have any further questions regarding the directed share issue, feel free to send us an e-mail on ir@fluoguide.com
Interview with Redeye on clinical update
8 June 2023
Presentation at Redeye Growth Day
1 June 2023
Presentation at ABGSC Life Science Summit
30-31 May 2023
Presentation at Sedermeradagen in Stockholm
30 May 2023
Presentation at Redeye Orphan Drugs Event
26 April 2023
Redeye Exclusive interview on Annual Report
28 February 2023
Presentation at Økonomisk Ugebrev Life Science Investor Conference
22 February 2023
Dansk Aktionærforening interview (in Danish)
24 Januar 2023
Presentation at Redeye Fight Cancer Seminar
19 January 2023